Peking Union Medical College

Revolutionary Evotip Workflow Enables Unprecedented Proteomic Analysis

Retrieved on: 
Wednesday, March 20, 2024
Medicine, Health, Plasma, Disease, Biomarker, Research, University, Developmental biology, Protein, Proteomics, University of Copenhagen, Peking Union Medical College, Mass spectrometry, Nature Communications

ODENSE, Denmark, March 20, 2024 /PRNewswire/ -- Evosep, a leading provider of sample preparation and separation solutions for mass spectrometry-based proteomics, is thrilled to announce the publication of a groundbreaking study in Nature Communications highlighting the capabilities of its innovative Evotip technology.

Key Points: 
  • This revolutionary approach simplifies and enhances the proteomic analysis of minimal cell quantities and liquid biopsies, setting a new standard in sensitivity, throughput, and robustness.
  • By streamlining sample preparation for mass spectrometry, the Evotip workflow enables the seamless, cost-effective identification of proteins from biological matrices like blood plasma.
  • "The One-Tip methodology streamlines proteomic analysis, enabling the identification of thousands of proteins from minimal cell quantities and single cells.
  • Our goal with Evotip is to simplify the proteomic analysis process, thereby enabling scientists to explore and understand biological systems," stated Morten Bern, CEO of Evosep.

Revolutionary Evotip Workflow Enables Unprecedented Proteomic Analysis

Retrieved on: 
Wednesday, March 20, 2024
Medicine, Health, Plasma, Disease, Biomarker, Research, University, Developmental biology, Protein, Proteomics, University of Copenhagen, Peking Union Medical College, Mass spectrometry, Nature Communications

ODENSE, Denmark, March 20, 2024 /PRNewswire/ -- Evosep, a leading provider of sample preparation and separation solutions for mass spectrometry-based proteomics, is thrilled to announce the publication of a groundbreaking study in Nature Communications highlighting the capabilities of its innovative Evotip technology.

Key Points: 
  • This revolutionary approach simplifies and enhances the proteomic analysis of minimal cell quantities and liquid biopsies, setting a new standard in sensitivity, throughput, and robustness.
  • By streamlining sample preparation for mass spectrometry, the Evotip workflow enables the seamless, cost-effective identification of proteins from biological matrices like blood plasma.
  • "The One-Tip methodology streamlines proteomic analysis, enabling the identification of thousands of proteins from minimal cell quantities and single cells.
  • Our goal with Evotip is to simplify the proteomic analysis process, thereby enabling scientists to explore and understand biological systems," stated Morten Bern, CEO of Evosep.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Retrieved on: 
Wednesday, January 3, 2024
APLM, Survival, Medicine, Prognosis, Greater, Disease, Incidence, Peking Union Medical College, Cancer, Acute myeloid leukemia, Patient, AML

This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.

Key Points: 
  • This Phase 3 bridging study is being performed in China with Chinese r/r AML patients.
  • Apollomics licensed uproleselan from GlycoMimetics (Nasdaq: GLYC), including the rights to clinical development, production and commercial sales in the Greater China market (Mainland China, Hong Kong, Macau and Taiwan).
  • “AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • AML remains a major unmet medical need in China with an incidence of close to 40,000 patients every year.

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HKEX, Rituximab, Lenalidomide, Toxicity, Treatment, Progression-free survival, Lymphoid leukemia, MCL, ASH, Aes, Refractory, Bleeding, Patient, Abstract, PFS, Impact, TLS, POLARIS, MRD, DOR, Pharmacokinetics, OLR, Atrial fibrillation, Medicine, SSE, ORR, Diarrhea, Cancer, Peking Union Medical College, Zhongshan Hospital, Fudan University, CRR, Infrared spectroscopy correlation table, Society, TTR, Relapse, B-cell lymphoma, Hospital, Pharmaceutical industry, Vaccine, Medical imaging, Management, Safety

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
  • The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
  • This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

Retrieved on: 
Monday, December 11, 2023
Huachung University, Multiple myeloma, Triple, Ophthalmology, HKEX, Safety, SAN, Hope, Treatment, Progression-free survival, ASH, Risk, Tongji Hospital station, Tongji Medical College, Patient, PFS, MRD, Marketing, Trial of the century, Medicine, VCN, Prognosis, Peking Union Medical College, ORR, Cancer, Survival, RRMM, BCMA, Quality of life, Society, Autoimmunity, Pharmaceutical industry, Medical device, Vaccine, Hematology

The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Key Points: 
  • The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.
  • As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients.
  • Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%.
  • Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative.

Shineco Opens Healthy Food Restaurant with Focus on Advanced Nutrition

Retrieved on: 
Monday, October 30, 2023
Taste, Dartmouth College, Health, Food, SISI, Lipid metabolism, Research, Metabolism, Trust, Peking Union Medical College, Hormone, Safety, Insulin resistance, Hygiene, Glucose, Insulin, Dietary supplement

BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”. Shineco’s first carry-out restaurant is located on Baihuazhou Road, Cangshan, Fuzhou City, China. Shineco’s official entry into the healthy food market represents a further evolution of the medical and health company’s operations, which has been long engaged in the field of life sciences.

Key Points: 
  • BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”.
  • Dr. Fengming Liu, the leader of Shineco’s Healthy Food Project, has a doctorate from Peking Union Medical College and is a postdoctoral fellow at Dartmouth College.
  • Shineco decided to enter the healthy food market in order to introduce life science concepts that encompass nutrition, health, and functionality while maintaining convenience, speed and taste.
  • The healthy carry-out meals launched by Shineco incorporates life science research that has given rise to using food to regulate insulin resistance and improve glucose and lipid metabolism.

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

Retrieved on: 
Sunday, October 22, 2023
Incidence, ESMO, Progression-free survival, Trae Waynes, DCR, Colorectal cancer, PFS, Hospital, KRAS, Medicine, Observation, Quality of life, Clinical trial, Peking Union Medical College, Pancreatic cancer, ORR, Lung cancer, SHP2, Safety, European Society for Medical Oncology, Patient, Fuda Cancer Hospital-Guangzhou, Pharmaceutical industry, NSCLC, Filippo Jacobio

The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.

Key Points: 
  • The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.
  • Jacobio presented results of a Phase I/IIa study of glecirasib in combination with JAB-3312.
  • The ORR was 86.7% (13/15) in the dose group[1] of 800 mg glecirasib in combination with 2 mg JAB-3312.
  • "The data provides the basis for the registrational clinical study of glecirasib in combination with SHP2 inhibitor.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Retrieved on: 
Wednesday, September 20, 2023
Linda, Malignancy, Obstetrics, Photocure, Peking Union Medical College Hospital, Medicine, NDA, Cervical cancer, Woman, Cevira, Human papillomavirus infection, Death, Incidence, SSE, Peking Union Medical College, Patient, HSIL, Cancer, HPV, Gynaecology, Mortality, WHO, Phase, NMPA, Safety, Bladder cancer, Pharmaceutical industry, Birth control, Colposcopy

Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

Key Points: 
  • Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
  • This study is a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • "It is exciting to see that the Phase III clinical trial for Cevira has met its primary endpoint.
  • This press release may contain product details and information which are not valid, or a product is not accessible, in your country.